14 June 2019

Information regarding our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska University Hospital

Since we get several questions about our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska University Hospital, we want to provide the following information on behalf of the company:

1. The study is fully recruited and ongoing
2. We plan to report the study’s outcome as soon as the study is completed and analysis of the study is completed in 2020.
3. The results are intended to form the basis for how we and the relevant authorities look at possible further studies
4. At present, we cannot provide other time frames for the study or our development program
5. We intend to post new information on our website as soon as the study results can be shared

Swedish version

Då vi får flera frågor kring vår pågående Amyotrophic Lateral Sclerosis (ALS) studie vid Sahlgrenska Universitets Sjukhuset vill vi ifrån företagets sida ge följande information:

1. Studien är fullrekryterad och pågår
2. Vi planerar att rapportera studiens utfall så snart studien är fullbordad och analys av studien är genomförd under 2020.
3. Resultaten avses ligga till grund för hur vi och berörda myndigheter ser på eventuella ytterligare studier
4. Vi kan i dagsläget inte ge några andra tidsramar till studien eller vårt utvecklingsprogram
5. Vi avser att lägga upp ny information på vår hemsida så snart studiens resultat kan delges

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

4 March 2019
TFS International AB (TFS) appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Viken – 4th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
8 February 2019
TIKOMED successfully closed fundraising of 8 Million Euros
Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its…
Read More
6 February 2019
Shadow Lake Group appointed Strategic Advisor and Business Development representative for the licensing process of IBsolvMIR® in Canada
Viken – 6th February 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
SEE MORE